Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
MorphoSys AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'MorphoSys AG - Product Pipeline Review - 2014', provides an overview of the MorphoSys AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of MorphoSys AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of MorphoSys AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of MorphoSys AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the MorphoSys AG's pipeline products Reasons to buy - Evaluate MorphoSys AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of MorphoSys AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the MorphoSys AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of MorphoSys AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of MorphoSys AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of MorphoSys AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 MorphoSys AG Snapshot 5 MorphoSys AG Overview 5 Key Information 5 Key Facts 5 MorphoSys AG - Research and Development Overview 6 Key Therapeutic Areas 6 MorphoSys AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 MorphoSys AG - Pipeline Products Glance 16 MorphoSys AG - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 MorphoSys AG - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 MorphoSys AG - Drug Profiles 20 MOR-208 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 NOV-3 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 MOR-202 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 BI-1 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 CNTO-5 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 NOV-7 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 PFE-1 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Monoclonal Antibodies For MRSA Infections 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Monoclonal Antibody for Oncology 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 MOR-206 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 MorphoSys AG - Pipeline Analysis 32 MorphoSys AG - Pipeline Products by Target 32 MorphoSys AG - Pipeline Products by Route of Administration 33 MorphoSys AG - Pipeline Products by Molecule Type 34 MorphoSys AG - Pipeline Products by Mechanism of Action 35 MorphoSys AG - Recent Pipeline Updates 36 MorphoSys AG - Dormant Projects 40 MorphoSys AG - Discontinued Pipeline Products 41 Discontinued Pipeline Product Profiles 41 MOR-203 41 MOR-101 41 MOR-102 41 MorphoSys AG - Locations And Subsidiaries 42 Head Office 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables MorphoSys AG, Key Information 5 MorphoSys AG, Key Facts 5 MorphoSys AG - Pipeline by Indication, 2014 8 MorphoSys AG - Pipeline by Stage of Development, 2014 9 MorphoSys AG - Monotherapy Products in Pipeline, 2014 10 MorphoSys AG - Partnered Products in Pipeline, 2014 11 MorphoSys AG - Partnered Products/ Combination Treatment Modalities, 2014 12 MorphoSys AG - Out-Licensed Products in Pipeline, 2014 14 MorphoSys AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 15 MorphoSys AG - Phase II, 2014 16 MorphoSys AG - Phase I, 2014 17 MorphoSys AG - Preclinical, 2014 18 MorphoSys AG - Discovery, 2014 19 MorphoSys AG - Pipeline by Target, 2014 32 MorphoSys AG - Pipeline by Route of Administration, 2014 33 MorphoSys AG - Pipeline by Molecule Type, 2014 34 MorphoSys AG - Pipeline Products by Mechanism of Action, 2014 35 MorphoSys AG - Recent Pipeline Updates, 2014 36 MorphoSys AG - Dormant Developmental Projects,2014 40 MorphoSys AG - Discontinued Pipeline Products, 2014 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.